ArticleSexually transmitted diseases2025
Efficacy of Doxycycline-Sitafloxacin Sequential Therapy for Urogenital Mycoplasma genitalium Infection in Nanjing, China.
Article in Sexually transmitted diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The Role of Antimicrobial Susceptibility and Resistance Testing forOpen forum infectious diseases · 2026Article
- Towards precision management ofFrontiers in cellular and infection microbiology · 2026Article
- Drug resistance ofFrontiers in cellular and infection microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe aim of this study was to evaluate the efficacy of doxycycline-sitafloxacin sequential therapy in the treatment of Mycoplasma genitalium (Mg) urogenital infections in Nanjing, China.
methodsPotential subjects were tested initially for Mg infection by nucleic acid amplification testing and again at least 21 days after completion of doxycycline (100 mg twice daily for 7 days)-sitafloxacin (100 mg twice daily for 7 days) sequential therapy. The presence of macrolide and quinolone resistance-associated mutations in 23S rRNA, parC, gyrA, and gyrB genes in Mg was examined at baseline and upon retesting of specimens from subjects that did not clear Mg.
resultsA total of 218 patients were screened for Mg, of whom 65 were positive for Mg; 63 Mg-infected patients were enrolled. Twenty-two (35%) Mg-infected subjects (16 heterosexual men, 5 women, and 1 man who had sex with men [MSM]) were successfully evaluated with a test of cure; 20 (91%) cleared Mg infection. In pretreatment specimens, mutations in 23S rRNA, parC (G248T [S83I]), gyrA (G277T [G93C]), and gyrB genes were present in 100% (19 of 19), 61.1% (11 of 18), 6.7% (1 of 15), and 7.1% (1 of 14), respectively. Mg clearance rates were 4 of 4 in infected subjects that possessed both wild-type parC and gyrA genes, and 9 of 10 when a parC G248T mutation and an otherwise wild-type gyrA gene were identified. Two subjects (9%) reported mild adverse events.
conclusionsDoxycycline-sitafloxacin sequential therapy was well tolerated and effective against most urogenital Mg infections in Nanjing and may provide an option for treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.